Pfizer India backs Karnataka FDA probe after counterfeit-drug repacking crackdown
Pfizer India says it is supporting Karnataka FDA’s investigation and removing affected batches after alleged counterfeit-drug repacking near Bengaluru. The regulator cancelled 16 drug licences and suspended eight, with products worth Rs 5.05 crore seized.
What happened
Pfizer India said it is supporting Karnataka FDA’s investigation into counterfeit medicines, removing affected batches whose numbers were copied. The regulator
Key facts
- 16 drug licences cancelled
- 8 drug licences suspended
- Rs 5.05 crore seized
- August 18 inspection
- Drugs and Cosmetics Act, 1940
What changed
Pfizer India said it is supporting Karnataka FDA’s investigation into counterfeit medicines, removing affected batches whose numbers were copied. The regulator cancelled 16 licences and suspended eight after busting an alleged repacking operation near Bengaluru.
Why this matters
Immediately quarantine affected batches, audit distributor and pharmacy traceability, and coordinate visibly with Karnataka FDA to protect patient safety and restore channel confidence.
What to watch
- FDA disclosure of the counterfeit products, batch numbers, manufacturers, therapeutic categories, and geographic distribution footprint.
- Whether seizures rise beyond Rs 5.05 crore or enforcement expands to additional warehouses, pharmacies, hospitals, or states.
- Evidence that suspect products entered Pfizer India's authorized distribution network versus being repacked outside it.
- Reports of adverse patient events, treatment failures, physician alerts, or hospital procurement recalls linked to the seized products.
- Additional licence cancellations, criminal charges, or directives for expanded testing, serialization, or recall activity.